Adherence to oral endocrine therapy by menopausal status: post hoc insights from a remote monitoring randomized trial.
무작위 임상시험
1/5 보강
Oral adjuvant endocrine therapy (AET) improves survival in hormone receptor-positive breast cancer, but younger, premenopausal women often struggle with adherence.
- 표본수 (n) 304
APA
Graetz I, Hu X, et al. (2026). Adherence to oral endocrine therapy by menopausal status: post hoc insights from a remote monitoring randomized trial.. NPJ breast cancer, 12(1). https://doi.org/10.1038/s41523-026-00900-9
MLA
Graetz I, et al.. "Adherence to oral endocrine therapy by menopausal status: post hoc insights from a remote monitoring randomized trial.." NPJ breast cancer, vol. 12, no. 1, 2026.
PMID
41605963
Abstract
Oral adjuvant endocrine therapy (AET) improves survival in hormone receptor-positive breast cancer, but younger, premenopausal women often struggle with adherence. In a post hoc analysis of a randomized trial (N = 304), app-based remote symptom monitoring improved 12-month AET adherence among premenopausal women (App-only: 53.9% vs. EUC: 25.0%), with no benefit for postmenopausal women. Findings suggest remote monitoring may help close adherence gaps in younger patients. Prospectively registered on ClinicalTrials.gov: NCT03592771.